HIT! High Impact Clinical Trials – What and Why

7 Feb 2025 14:15 15:45
Brahmkamal Hall - Plenary Hall
Andrea Viecelli Chair SwitzerlandUniversity Hospital of Zurich
VivekKumar Chair IndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India

Time Session
14:15
14:45
Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)
HIT1-1
RajivAgarwal Oral Abstract Presenter United States
14:45
15:15
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
HIT1-2
BradRovin Oral Abstract Presenter United StatesThe Ohio State University
15:15
15:45
Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
HIT1-3
KatherineTuttle Oral Abstract Presenter United StatesUniversity of Washington School of Medicine, Division of Nephrology